← Russell 3000 cross-section

OGN Organon & Co.

Trailing twelve months to 2026-06-30 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$3.6bn
Revenue TTM
$6.1bn
Net income TTM
$209m
Free cash flow
$567m
Composite score
Sector rank
#1287

Valuation

P / E
17.3
EV / EBITDA
EV / sales
1.8
FCF yield
15.69%
Earnings yield vs 10-yr
1.05pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
3.4%
EBITDA margin
ROE
20.8%
ROIC
Revenue growth
-2.5%

Insider activity, last 90 days

Net open-market
$-0.20m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Sebela Pharmaceuticals (“Sebela”) On February 19, 2026, we entered into an exclusive license agreement with Sebela for the global rights to Miudella ®, a hormone-free copper intrauterine device (“IUD”) that was approved by the FDA on February 24, 2025 and is estimated to launch commercials sales in the United States in late 2026. Under the terms of the agreement, we paid $27.5 million in June 2026, with potential sales-based milestone payments of up to $505 million, and tiered double-digit royalties based on net sales. …Organon & Co., 10-Q, period ended 2026-06-30, filed 2026-07-31

Read the full passage →